Brain cancer's notorious resistance to immunotherapy may stem from a metabolic communication network that actively suppresses immune surveillance. Glioblastoma tumors appear to orchestrate their own protection by hijacking normal cellular energy exchange pathways to create an invisible shield against immune attack.
The discovery centers on lactate transport between tumor-associated macrophages and glioblastoma stem cells via MCT4-MCT1 transporters. When macrophages deliver lactate to cancer stem cells, it triggers lactylation of the DNA repair protein KU70 at lysine 317, effectively silencing the cGAS-STING pathway that normally alerts the immune system to cellular damage. This metabolic handoff transforms what should be tumor-fighting macrophages into unwitting accomplices that feed cancer growth while suppressing immune recognition.
This mechanism represents a sophisticated tumor defense strategy that extends beyond simple immune evasion. Most immunotherapy approaches focus on removing immune brakes or enhancing T-cell activation, but this finding reveals tumors actively jamming the cellular alarm systems that initiate immune responses. The lactylation-mediated silencing of cGAS-STING represents a foundational block in the immune recognition cascade.
Combining lactate transport inhibition with checkpoint blockade therapy showed additive benefits in experimental models, suggesting metabolic intervention could enhance existing immunotherapies. However, the complexity of safely disrupting lactate metabolism—essential for normal cellular function throughout the body—presents significant therapeutic challenges. The approach remains promising but requires careful optimization to target tumor-specific metabolic dependencies without compromising healthy tissue function.